Literature DB >> 114208

The crystallizable human myeloma protein Dob has a hinge-region deletion.

L A Steiner, A D Lopes.   

Abstract

During experiments to prepare heavy-metal derivatives of the crystallizable human IgG1 (k) immunoglobulin Dob, it became apparent that this protein has several unusual features. (1) Instead of the four labile interchain disulfide bridges ordinarily found in IgG1, the Dob protein has only a single interchain disulfide bridge, which connects its two light chains. (2) The Dob heavy chain appears to be slightly smaller than a control gamma1 chain, as judged by polyacrylamide gel electrophoresis in sodium dodecyl sulfate and by gel filtration in guanidine. (3) The Dob heavy chain has three fewer residues of half-cystine than expected in gamma1 chains. (4) The Dob IgG is relatively resistant to digestion with papain and trypsin; however, it is readily digested with pepsin, although at an unusual site. These findings suggest that some or all of the gamma1 hinge region is missing in Dob. To localize the deletion, we prepared an F(ab')2 fragment consisting of two heavy-chain pieces (Fd') noncovalently associated with the light-chain dimer. The Fd' piece was isolated and digested with trypsin. The sequence of the C-terminal tryptic peptide was Val-Ala-Pro-Glu-Leu-Leu-Gly-Gly-Pro-Ser-Val. Positions 2-11 of this peptide are identical with residue positions 231-240 of the gamma1 chain. The N-terminal valine could be either Val-211 or Val-215 of the gamma1 sequence. A tryptic peptide, Val-Asp-Lys-Lys, was also isolated from Dob Fd'; this sequence is not found in the variable region of the Dob heavy chain [Steiner, L. A., Garcia Pardo, A., & Margolies, M. N. (1979) Biochemistry (following paper in this issue)] but corresponds to positions 211-214 of the gamma1 constant region. Therefore, the deletion cannot include these residues and must begin after Val-215; normal gamma1 sequence resumes at Ala-231. The same 15-residue deletion has been found in two other IgG1 proteins, Mcg [Fett, J. W., Deutsch, H. F., & Smithies, O. (1973) Immunochemistry 10, 115] and Lec [Rivat, C., Schiff, C., Rivat, L., Ropartz, C., & Fougereau, M. (1976) Eur. J. Immunol. 6, 545]. Possible explanations for the occurrence of identical hinge-region deletions in three different immunoglobulins are suggested by recent experiments demonstrating that the three constant domains and the hinge region of mouse gamma1 chains are each encoded by separate segments of DNA [Sakano, H., Rogers, J. H., Hüppi, K., Brack, C., Traunecker, A., Maki, R., Wall, R., & Tonegawa, S. (1979) Nature (London) 277, 627].

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114208     DOI: 10.1021/bi00586a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Three-dimensional structure of a human immunoglobulin with a hinge deletion.

Authors:  L W Guddat; J N Herron; A B Edmundson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

2.  Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.

Authors:  M Klein; N Haeffner-Cavaillon; D E Isenman; C Rivat; M A Navia; D R Davies; K J Dorrington
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

3.  Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy.

Authors:  D F Moorhouse; R I Fox; H C Powell
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

4.  Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology.

Authors:  Haruki Hasegawa
Journal:  Int J Cell Biol       Date:  2013-03-05

Review 5.  IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development.

Authors:  Danlin Yang; Rachel Kroe-Barrett; Sanjaya Singh; Christopher J Roberts; Thomas M Laue
Journal:  MAbs       Date:  2017-08-16       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.